Clinical Trial

Gilteritinib in Combination With Venetoclax and Azacitidine for AML Patients With FLT3 Mutations Ineligible for Intensive Treatment

Study acronym: SEQUENCE
Recruiting Phase 2
View on ClinicalTrials.gov →
Summary
Explore the best tolerable and efficacious dose of Gilteritinib when combined with standard treatment with Venetoclax and Azacitidine in AML patients with FLT3 mutations which are ineligible for intensive chemotherapy
Protocol Amendment History 2 amendments
This ClinicalTrials.gov record has been amended 2 times since 2024-11-19; most recent amendment 2025-05-27.
Status change: Not Yet Recruiting → Recruiting 2025-05-27
Trial Details
NCT Number NCT06696183
Lead Sponsor Technische Universität Dresden
Conditions AML - Acute Myeloid Leukemia
Enrollment 60 participants
Start Date 2025-04-25
Primary Completion 2029-04 (estimated)
Study Completion 2030-04 (estimated)
Updated on ClinicalTrials.gov 2025-05-29